Equity futures were mixed following a mixed regular session, as profit-taking and risk aversion appeared to take hold ahead of the forthcoming jobs report. Of note, however, President Trump instructed his “representatives” to purchase $200B of mortgage bonds, sending shares of companies such as Opendoor (OPEN) and Offerpad (OPAD) higher. This marks the second day in a row Trump released commentary on Truth Social that resulted in bullish sentiment for a sector, after his comments on expanding military spending on Wednesday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Check out this evening’s top movers from around Wall Street, compiled by The Fly.
HIGHER AFTER TRUMP INSTRUCTS ‘REPRESENTATIVES’ TO BUY $200B OF MORTGAGE BONDS –
- Offerpad Solutions (OPAD) up 64.5%
- Opendoor Technologies (OPEN) up 12.4%
- Rocket Companies (RKT) up 7%
- UWM Holdings (UWMC) up 5.1%
ALSO HIGHER –
- Jazz Pharmaceuticals (JAZZ) up 5% after naming Thomas Riga chief business officer
- MGM Resorts (MGM) up 0.7% after Texas Capital initiated coverage of the stock with a Buy rating
LOWER AFTER EARNINGS –
ALSO LOWER –
- AXT Inc. (AXTI) down 29% after cutting its Q4 guidance
- Olin (OLN) down 7.8% after updating its Q4 outlook
- General Motors (GM) down 1.6% after saying it expects an additional $6B in charges related to a review of EV capacity and investments
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer
- Jazz Pharmaceuticals price target raised to $225 from $205 at Morgan Stanley
- Buy Rating on Jazz Pharmaceuticals Driven by Zanidatamab’s Differentiated Efficacy and Clear Regulatory Path in First-Line HER2+ GEA
- BeOne Medicines says HERIZON-GEA-01 met dual primary endpoint of PFS
- Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial